The Service Line

Hospital cancer clinics will be paid average sales price minus 28 percent for drugs bought through the 340B program starting January 1, a gentler cut than the 33.4 percent proposed in July, but still a $4.35 billion first-year hit to Medicare drug payments. The Centers for Medicare and Medicaid Services (CMS) issued the Calendar Year 2027 hospital outpatient final rule (CMS-1850-F) November 4, and its final rule fact sheet says the rate rests on CMS’s own drug acquisition cost survey, which ran January 1 through April 7. CMS projects beneficiary drug payments fall $1.1 billion in year one, about $900 for the average patient who receives a qualifying drug, and the savings are redistributed to non-drug outpatient services under budget neutrality. The fact sheet names no exemption from the cut for rural or cancer hospitals. In the same rule, the offset that claws back the earlier 340B remedy rises from 0.5 percent to 2 percent a year (CMS had floated 3 percent) until $7.8 billion is recovered, which CMS estimates happens in 2031. The rule governs hospital outpatient departments, not independent practices, so the pressure on independents is competitive: the hospital clinic down the road loses its drug-margin advantage. Confidence: High on the rate and dollar figures as stated by CMS; Medium on the competitive read-through.

Reimbursement

The final 2027 physician fee schedule cuts the base rate again and locks in a bigger billing bonus for doctors in value-based arrangements. CMS issued the final rule November 4. According to Applied Policy’s summary, the conversion factor falls to $32.6286 for most clinicians (down 2.31 percent) and $32.9548 for those in a qualifying alternative payment model (down 1.83 percent), worse than the July proposal, mainly because a one-year 2.5 percent statutory bump expires. The G2211 complexity add-on code is replaced as proposed by two percentage modifiers: B1 pays 16 percent of the visit, and B2 pays 32 percent for eligible Medicare Shared Savings Program and LEAD Model participants. For an oncology group that bills heavy on high-level visits, the B2 route is now a real revenue lever, and it counts toward ACO benchmarks. The same rule makes quarterly Part D 340B claims reporting mandatory, with the first quarter’s data due September 30, 2027. The Community Oncology Alliance praised the 340B hospital cut but said the physician payment cuts still threaten practices and urged Congress to act in the lame-duck session. We could not find how the final rule treated drug administration or radiation oncology codes, so we make no claim there. Confidence: High on conversion factors and modifiers; Medium on reporting details (secondary summary).

Enforcement

No oncology-specific enforcement action surfaced in the Department of Health and Human Services (HHS) Office of Inspector General enforcement actions page for November 1 through 11; the newest entries were November 6 and none named cancer care. We could not load the Justice Department’s news page this run, so we cannot rule out a U.S. Attorney’s Office release. The latest chemotherapy-billing case we have verified remains the July 1 Maryland settlement covered earlier.

Who’s Buying

Cencora’s $2.4 billion bid for American Oncology Network (AON) still has no closing date. Cencora’s fiscal fourth quarter earnings release, filed November 4, lists the signed agreement for the 350-provider, 21-state network among its recent highlights and gives no timing; the original deal release conditions closing on regulatory clearances and AON stockholder approval. We found no proxy statement or merger filing since. Practice owners weighing their own offers should note what the terms still leave unsaid: purchasing, ancillary revenue and governance after closing. Confidence: High on the filings; we did not review the earnings call transcript.

Clinical Policy

The Food and Drug Administration (FDA) approved two oncology drugs this week that matter to practice economics in different ways. On November 5 the agency gave accelerated approval to Johnson & Johnson’s Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for recurrent or metastatic head and neck squamous cell carcinoma that has progressed after platinum chemotherapy and an anti-PD-(L)1 drug, not for HPV-associated oropharyngeal cancer. The hyaluronidase pairing signals an under-the-skin formulation, which in practice shortens chair time (our inference; the FDA notice does not state the route). On November 10 it approved EMD Serono’s pimicotinib (Pimjetmi) for symptomatic tenosynovial giant cell tumor where surgery risks severe morbidity. Both are listed on the FDA’s oncology approval notifications page. Confidence: High on indications and dates.

Frontier scan, supply: chemotherapy shortages are not over. Trade coverage of the American Society of Health-System Pharmacists (ASHP) tracking, in Becker’s Hospital Review, reports carboplatin as the most constrained platinum drug with some formulations not expected back until 2027, cisplatin nearer pre-shortage levels, and cytarabine and irinotecan newly added in October. For a practice, the issue is substitution and documentation when a preferred vial is unavailable. Confidence: Medium, trade source; check ASHP’s list directly before acting.

The Operator Metric

On a drug with a $10,000 average sales price, Medicare’s payment to a 340B hospital falls from $10,600 to $7,200 on January 1, a $3,400 swing. That is our arithmetic from CMS’s rates (average sales price plus 6 percent before, minus 28 percent from January 1), per the CMS fact sheet, and it is what Medicare pays the hospital, not the hospital’s profit, since acquisition cost is not public per claim. Track it against the 7.5 percent budget-neutral lift CMS applies to non-drug services (5.5 percent after the 2 percent offset, per Targeted Oncology), which tells you whether a hospital outpatient clinic is a net winner or loser in 2027. Confidence: Medium, yardstick only.